Zymeworks Inc. Common Stock
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $556.37 million
- Book Value:
- Revenue TTM:
- $446.14 million
- Operating Margin TTM:
- Gross Profit TTM:
- $203.78 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Zymeworks Inc. Common Stock had its IPO on 2017-04-28 under the ticker symbol ZYME.
The company operates in the Healthcare sector and Biotechnology industry. Zymeworks Inc. Common Stock has a staff strength of 304 employees.
Shares of Zymeworks Inc. Common Stock opened at $8.5 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $8.38 - $8.68, and closed at $8.67.
This is a +2.12% increase from the previous day's closing price.
A total volume of 210,784 shares were traded at the close of the day’s session.
In the last one week, shares of Zymeworks Inc. Common Stock have slipped by -1.48%.
Zymeworks Inc. Common Stock's Key Ratios
Zymeworks Inc. Common Stock has a market cap of $556.37 million, indicating a price to book ratio of 1.7819 and a price to sales ratio of 13.3063.
In the last 12-months Zymeworks Inc. Common Stock’s revenue was $446.14 million with a gross profit of $203.78 million and an EBITDA of $180.72 million. The EBITDA ratio measures Zymeworks Inc. Common Stock's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Zymeworks Inc. Common Stock’s operating margin was 39.16% while its return on assets stood at 21.19% with a return of equity of 45.67%.
In Q1, Zymeworks Inc. Common Stock’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1756.9%.
Zymeworks Inc. Common Stock’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $2.88 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zymeworks Inc. Common Stock’s profitability.
Zymeworks Inc. Common Stock stock is trading at a EV to sales ratio of 5.8898 and a EV to EBITDA ratio of -0.8146. Its price to sales ratio in the trailing 12-months stood at 13.3063.
Zymeworks Inc. Common Stock stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $600.74 million
- Total Liabilities
- $67.32 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Zymeworks Inc. Common Stock ended 2023 with $600.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $600.74 million while shareholder equity stood at $-583116000.00.
Zymeworks Inc. Common Stock ended 2023 with $0 in deferred long-term liabilities, $67.32 million in other current liabilities, 909916000.00 in common stock, $-583116000.00 in retained earnings and $12.02 million in goodwill. Its cash balance stood at $181.58 million and cash and short-term investments were $412.38 million. The company’s total short-term debt was $3,372,000 while long-term debt stood at $0.
Zymeworks Inc. Common Stock’s total current assets stands at $426.37 million while long-term investments were $72.47 million and short-term investments were $159.21 million. Its net receivables were $66.92 million compared to accounts payable of $6.43 million and inventory worth $0.
In 2023, Zymeworks Inc. Common Stock's operating cash flow was $0 while its capital expenditure stood at $386000.
Comparatively, Zymeworks Inc. Common Stock paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Zymeworks Inc. Common Stock stock is currently trading at $8.67 per share. It touched a 52-week high of $10.8 and a 52-week low of $10.8. Analysts tracking the stock have a 12-month average target price of $14.
Its 50-day moving average was $9.08 and 200-day moving average was $7.83 The short ratio stood at 11.73 indicating a short percent outstanding of 0%.
Around 499.1% of the company’s stock are held by insiders while 10111.7% are held by institutions.
Frequently Asked Questions About Zymeworks Inc. Common Stock
Similar Industry Stocks (Biotechnology)
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include Zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.